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Abstract
Radiotherapy and radiology have been indispensable components in cancer care for many years. The detection
limit of small tumor foci as well as the development of radio-resistance and severe side effects towards normal
tissues led to the development of strategies to improve radio-diagnostic and -therapeutic approaches by
pharmaceuticals. The term “radiopharmaceutical” has been used for drugs labeled with radioactive tracers for
therapy or diagnosis. In addition, drugs have been described to sensitize tumor cells to radiotherapy
(radiosensitizers) or to protect normal tissues from detrimental effects of radiation (radioprotectors). The present
review summarizes recent concepts on the transport of radiopharmaceuticals, radiosensitizers, and radioprotectors
in cells and tissues, e.g. by ATP-binding cassette transporters such as P-glycoprotein. Strengths and weaknesses of
current strategies to improve transport-based processes are discussed.
Keywords: ABC transporter, Multidrug resistance, Radioresistance, Radioprotection, Radiochemotherapy
Introduction
Together with surgery and chemotherapy, radiotherapy
represents one of the main pillars of cancer therapy.
The field of radiology for image-based cancer diagnos-
tics experiences rapid progress in the past years making
both radiotherapy and -diagnostic to indispensible com-
ponents in cancer care.
A number of strategies have been developed to
increase efficacy of radiotherapeutic and -diagnostic
approaches by pharmaceuticals. This represents exciting
interdisciplinary opportunities for research in medicine
and physics on the one hand and pharmacy and phar-
macology on the other hand.
Traditionally, the term “radiopharmaceutical” has been
used for drugs labeled with radioactive tracers for thera-
peutic or diagnostic purposes. Due to the enormous
progress in the past decade, the interface between drug
treatment and radiotherapy became much broader.
Many drugs have been described to sensitize tumor cells
to radiotherapy or to protect normal tissues from radia-
tion-induced injuries. In a broader sense, those drugs
are also “radiopharmaceuticals”.E v e nd r u g sw h i c h
increase the efficacy of other forms of radiation-based
therapy have to be named in this context, e.g. 8-methox-
ypsoralen in UVA-therapy or enhancers of photody-
namic drugs. In order to avoid confusion with the term
“radiopharmaceutical” in the narrow sense, we propose
the term radiomodulator for drugs sensitizing tumor
cells or protecting normal tissues to all forms of radia-
tion therapy.
The multiple and partly heterogeneous aspects of
radiopharmaceuticals and -modulators can be separated
into three major fields:
(1) Radiopharmaceuticals are used in nuclear medi-
cine as tracers for diagnostics and therapy of many
diseases. Technetium 99m (Tc-99m) serves as
gamma-rays-emitting tracer nuclide for many radio-
pharmaceuticals. More than 30 different Tc-99m-
based radiopharmaceuticals are known, which are
used for imaging and functional studies in diverse
organs, e.g. brain, lung, kidneys, liver, skeleton etc.
[1]. They also serve for diagnostic visualization of
tumors. Moreover, numerous radiopharmaceuticals
have been developed with other radioisotopes than
Tc-99m. Their localization in the body is also deter-
mined by gamma-ray measurement. Radioisotopes
suitable for this purpose are Fluor-18, Gallium-67,
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esting treatment option is boron neutron capture
therapy (BNCT) which is based on the neutron cap-
ture reaction of the stable isotope
10Bb yi r r a d i a t i n g
this isotope with thermal neutrons (En<0.1 KeV), the
ionized particles
4He and
7Li are generated from the
10B(n,a)
7Li reaction [2]. Preloading of cells with spe-
cific markers can be used for the treatment of speci-
fic cancer types [3].
(2) Radiosensitizers: About one half of all patients
with a solid tumor are treated by radiotherapy. The
effectiveness of this treatment option is, however,
frequently hampered by the development of radio-
resistance [4]. Therefore, the combination of radio-
therapy with drugs to sensitize tumors towards
radiotherapy is an attractive strategy [5,6]. At the
same time, the radiation effects on normal tissues
should not be increased by radio-sensitizing agents.
Ionizing radiation causes DNA damage by the genera-
tion of reactive oxygen species (ROS), especially DNA
double strand breaks. Diverse established anticancer
agents have been described to sensitize tumors towards
radiotherapy by interaction with DNA biosynthesis (5-
fluorouracile, gemcitabine, hydroxyurea) [7] or inhibition
of DNA-replication and repair by adduct formation
(temozolomide, cisplatin) [8,9]. DNA topoisomerase
inhibitors (topotecan, irinotecan) have also been shown
to exert radio-sensitizing effects [10]. Mitotic spindle
poisons (paclitaxel, docetaxel) arrest tumor cells in the
G2M phase of the cell cycle[11].
Frequently, hypoxic areas are found in tumors. As
oxygen is necessary for the formation of radical mole-
cules, which are important in radiotherapy, hypoxic
tumors are radio-resistant. Various strategies have been
advised to overcome this problem, e.g. re-oxygenation of
hypoxic tumors (nitroimidazole compounds, efaproxiral),
the activation of intracellular reductases by bioreductive
cell poisons (tirapazamine) or the inhibition of the
hypoxia-inducing factor (HIF-1) [12,13]. HIF-1 inhibi-
tors are more in the focus of interest, as nitroimidazoles
reveal a narrow therapeutic window.
In the past years, rational radio-sensitizing concepts
have been investigated, which are based on the inhibi-
tion of specific target proteins [14]. Examples are inhibi-
tors of specific repair enzymes for radiation-induced
damage (ATM kinase), DNA-PK, Chk1 and Parp-1 (e.g.
caffeine, [15,16] as well as inhibitors of epidermal
growth factor receptor (EGFR) pathway (cetuximab,
erlotinib) and inhibitors of downstream signaling routes
(wortmannin). Radio-sensitizing effects have also been
observed by inhibitors of the NF-B transcription factor
and substances, which switch off radiation-induced
apoptosis (p53 modulators, Bcl-2 inhibitors).
Trichostatin A inhibits histone deacetylases and gelda-
namycin blocks the heat shock protein, HSP90. The
suppression of blood vessel formation in tumors (neoan-
giogenesis) gained much attention in the past years.
Interestingly, various angiogenesis inhibitors, e.g. block-
ers of the vascular endothelial growth factor (VEGF)
also exert radio-sensitizing effects.
Special forms of radiosensitizers are photosensitizers,
i.e. chemical compounds excited by visible or near-infra-
red light. If accumulated in tumors and illuminated by
light, photo-sensitizers generate singlet oxygen destroy-
ing tumor cells [17-19]. Broadband ultraviolet B (BB-
UVB), and psoralen plus and ultraviolet A (PUVA), and
more recently narrowband UVB (NB-UVB) are skin-
directed phototherapies used to treat cutaneous T-cell
lymphoma. Extracorporeal photopheresis (ECP) is effec-
tive in more advanced stage disease [20-22].
In photodynamic therapy (PDT), photosensitizers such
as photofrin are excited by light of a specific wavelength.
Interestingly, some types of photosensitizers are sub-
strates of Breast Cancer Resistance Protein (BCRP,
ABCG2) leading to resistance of tumors to PDT [23].
For example, A431 lung cancer cells transfected with
BCRP were more resistant to photofrin-PDT than A431
control cells in vitro and fumitremorgin C, a specific
BCRP inhibitor, reversed this resistance [24]. A clinical
study with 81 lung cancer patients showed that the effi-
cacy of photofrin-PCT in cancer lesions was significantly
affected by the expression of BCRP [24].
Genetic polymorphisms and transcriptional activation
in the ABCG2 (BRCP) transporter influenced cellular
accumulation of porphyrin derivatives in cancer cells
leading to individual differences of patients in their
response to photodynamic therapy [23].
(3) Radioprotectors: Protection from radiation-
induced damage is important to
￿ avoid radiation damage in healthy tissue and
organs during radiotherapy of tumors
￿ save personnel of airlines from excessive exposure
to radiation in the air.
Various natural products and synthetic compounds
have been described as radioprotectors [25]. They can
be separated in four categories:
(a) Scavenger of ROS and other radical molecules.
Selen and selenoproteins exert anti-oxidant, radio-
protective and anti-carcinogenic effects. A possible
effector of this radio-protective effect is glutathione
peroxidase. This opens the possibility that nutritional
supplementation with L-selenomethionine might
represent a suitable radioprotector for airline per-
sonnel [26].
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are N-acetyl-L-cysteine (NAC), tocopherol succinate
(a vitamin E analogue) and eugenol. Resveratrol and
other polyphenols activate Sirt1 expression. Sirtuins
are NAD
+-dependent deacetylases, which interact
with the NBS1 DNA repair protein, thereby regulat-
ing DNA damage repair. Furthermore, resveratrol
suppresses inflammatory processes by inhibition of
prostaglandin production, COX2 expression and
NFB activity. Resveratrol also induces G1 and G1/S
cell cycle arrest and apoptosis [26,27].
(c) Manganese-dependent superoxide dismutase
(MnSOD) is an anti-oxidant enzyme. Small molecule
MnSOD inhibitors and gene-therapeutic strategies
based on MnSOD have been described to lower cel-
lular ROS levels for radio-protection [27].
(d) Amifostine and its active metabolite, WR-1065,
are non-protein-thiols, scavenging ROS and other
radical molecules. Thereby, they support DNA
damage repair and influence intracellular hypoxia by
auto-oxidation processes [27].
(e) Improvement of DNA damage repair and modu-
lation of signal transduction after DNA damage.
Amifostine also inhibits DNA topoisomerase II lead-
ing to the arrest of damaged cells in the G2Mp h a s e
of the cell cycle. Thereby, the homologous recombi-
nation DNA repair pathway in the G2Mp h a s ei s
more effective [27].
(f) Inhibition of apoptosis in radiation-damaged cells.
Flagellin is a natural product of bacteria. The flagel-
lin derivative, CBLB502, activates NFB via the toll-
like receptor-5 (TLR-5) and inhibits the onset of
apoptosis. The synthetic small molecule, PD
0332991 inhibits CDK-4 and -6 and protects from
radiation damage by induction of Ras-mediated cel-
lular quiescence and inhibition of apoptosis [28,29].
Transport through bio-membranes
The first barrier for drugs represents the entry from the
body surface to the body inside (absorption). In this
context, the inside of the gastrointestinal tract is under-
stood as body surface. The cellular structures separating
the outside of the body from the inside are lipid bilayer-
consisting cell membranes. Hence, the passage through
bio-membranes is a precondition for drug activity.
This can happen by diverse mechanisms [30]:
(1) Lipophilic substances enter cell membranes by
passive diffusion or passive transport (carrier) with-
out energy, i.e. ATP consumption.
(2) Hydrophilic compounds enter cell membranes by
passive transport (e.g. ion channels) or active trans-
port (ATP-consuming transport).
(3) For vesicular transport, extracellular compounds
are included into vesicles, which constrict into the
intracellular space (phagocytosis, pinocytosis).
(4) For receptor-mediated endocytosis, compounds
bind to receptors on the cell surface. Receptor-
ligand-complexes are accumulated in coated pits of
the cell membrane and are internalized by
endocytosis.
There are three super-families of ATP-consuming
transporters with eminent relevance for drug transport:
(1) ATP-binding cassette (ABC) transporter. This
family consists of 49 members in the human genome
[31-33]. The multidrug resistance-mediating trans-
porters P-glycoprotein (ABCB1, MDR1), multidrug
resistance-related proteins (ABCC, MRP), and the
breast cancer resistance protein (ABCG2, BCRP)
belong to this family [34,35]. They confer resistance
towards anticancer drugs in tumors. In healthy tis-
sues and organs they have a protective function
towards xenobiotic compounds, e.g. in the blood-
brain-barrier [36].
(2) The solute carrier (SLC) superfamily contains
members with very diverse functions. The subfami-
lies, SLC6A, 10A, 15A, 16A, 17A, 22A and 29 A are
associated with the transport of xenobiotics. These
subfamilies consist of organic anion transporters,
organic cation transporters, nucleoside transporters,
amino acid and peptide transporters [37].
(3) The sodium-independent large organic anion
transporters (SLCO) are a third superfamily involved
in drug transport. Previously, they were assigned to
the SLC superfamily as SLC21A subfamily, but now
they consist of an own gene family [38,39].
In addition to drug uptake, the distribution in tis-
sues and organs are essential for drug activity. Drugs
are frequently bound to transfer proteins. As an
example, albumin binds many different free drug
molecules in the blood. Moreover, there are more
specific transfer molecules, which only bind certain
drug classes, e.g. a-tocopherol-binding proteins or
transferrin, which binds iron and enables its uptake
into cells [40,41].
Unambiguously, drug transport is of eminent impor-
tance for drug activity. This is true for radiopharma-
ceuticals as well as radiomodulators. There was a
thriving development in this field in the past years,
which is a fertile ground for exciting novel research
concepts in the years to come. A synopsis of cellular
transport processes described in this review is depicted
in Figure 1.
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A well-known radiotracer for positron emission tomo-
graphy (PET) is 2-[
18F] fluoro-2-deoxy-D-glucose (FDG)
(Figure 2). Tumor imaging by FDG-PET is based on a
fundamental observation of Otto Warburg in the first
half of the 20
th century. He found that cancer cells take
up more glucose than normal cells. Despite reduced
oxygen consumption, they have higher glycolysis rates
[42]. FDG is taken up by tumor cells via the glucose
transporters, GLUT1 and GLUT4. Intracellularly, FDG
is phosphorylated to FDG-6-phosphate without further
metabolization. Thereby, it is accumulated more in
tumors than in normal surrounding tissues. Tumor cells
express more GLUT1 than normal cells.
Though FDG-PET is already established in clinical
routine diagnostics [43], there are several problems. The
GLUT1 expression largely varies from tumor type to
tumor type affecting FDG uptake. Proliferation rate,
hypoxia, inflammatory infiltrates and even blood sugar
level all influence FDG uptake. Hence, there is an urgent
need for novel radiotracers with more specific target
properties [44].
The sodium-iodide symporter (NIC) uses the sodium
gradient built up by sodium-potassium ATPase in the
cell membrane for the co-transport of iodide and
sodium into the cell. This co-transport can be especially
observed in the pituitary, lactating breast epithelia as
well as sweat glands and in stomach mucosa [45].
Therefore, these tissues accumulate the radioactive iso-
topes,
123I and
131I as well as
99mTc-pertechnetates. This
can be used in nuclear medicine for diagnosis and ther-
apy of pituitary diseases [46].
P-glycoprotein (ABCB1, MDR1)i sw e l l - k n o w ni n
terms of its function for multidrug resistance of tumors
[31,33]. Two major therapy concepts have been devel-
oped with P-glycoprotein as target molecule:
￿ Pharmacological inhibition of P-glycoprotein and,
thereby, the re-sensitization of multidrug-resistance
￿ MDR1- based gene therapy of healthy bone mar-
row cells to confer resistance towards high-dose che-
motherapy. High concentrations of anticancer drugs
would kill tumor cells but spare healthy bone mar-
row because of the gene therapeutic MDR1
expression.
For both concepts, non-invasive molecular imaging
techniques are desired to predict and monitor treatment
success. For this purpose, various g-ray-emitting sub-
stances have been developed, which are transport sub-
strates of P-glycoprotein. The best-known
radiopharmaceuticals in this context are
99mTc-sestamibi
[47,48] and
99mTc-Tetrofosmin [49]. P-glycoprotein-
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Figure 1 Synopsis of cellular transport processes. (A) Transport
of radiopharmaceuticals; (B) transport of radiosensitizers; (C)
transport of radiomodulators. Abbreviations: 17-AAG, 17-allylamino-
demethoxygeldanamycin; a-TTP, alpha-tocopherol transfer protein;
ABCA1, ATP-binding cassette transporter A1; BCRP, breast cancer
resistance protein; CETP, colesterylester transfer protein; GLUT1/4,
glucose transporter 1/4; HDLR, high density lipid receptor; LDLR, low
density lipid receptor; MRP, multidrug resistance-related protein; P-
gp, P-glycoprotein; PLTR, phospholipid transfer protein;, SCARB1,
scavenger receptor-class BI-
Figure 2 Whole body images 2 h after i.p. injection (horizontal
slices, thickness 7 mm). Free [
18F]FDG is taken up by high-glucose
using cells such as brain, heart and testis and excreted via kidney
and bladder. Liposomal encapsulated [
18F]FDG accumulates in the
abdomen of the rat. Only released [
18F]FDG can be taken up into
organs (Picture taken from [41]).
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compounds out of the cell whereas P-glycoprotein-nega-
tive, drug-sensitive tumor cells accumulate the sub-
stances. This uptake can be visualized as hot spots by
scintigraphy. The realization of this strategy has been
demonstrated in several proof-of-principle clinical trials.
The conclusion of these studies was that both sub-
stances are able to predict multidrug-resistance of
tumors caused by P-glycoprotein [50-53].
99mTc-sesta-
mibi revealed P-glycoprotein specificity in cancer
patients. An MRP1-related transport of this compound
could not be detected, although this was observed in
preclinical models in vitro [49,54].
99mTc-Tetrofosmin
was also found to be transported by MRP1 in vitro
[54,55]. In a clinical trial,
99mTc-MIBI accumulation in
patients correlated with the absence of both P-glycopro-
tein and MRP1 expression, indicating that
99mTc-MIBI
is also transported by MRP1 [56]. Similar results have
been found for
99mTc-Tetrofosmin in lymphoma
patients [57].
Transport of radiosensitizers
Many established anticancer agents used to sensitize
radiation effects in combined radiochemotherapy are
substrates of drug transporters. Mitotic spindle poisons
such as paclitaxel and docetaxel are well-known sub-
strates of P-glycoprotein. Camptothecin derivatives
(topotecan, irinotecan) are transported by BCRP
(ABCG2). Multidrug resistance-related proteins of the
ABCC subfamily of ABC transporters confer resistance
towards cisplatin, 5-fluorouracil and gemcitabine. More-
over, copper transporters (e.g. CTR1) and volume-sensi-
tive chloride channels also contribute to cisplatin
resistance. Changes of membrane fluidity are a further
factor of drug resistance. In as much as transport pro-
cesses influence drug resistance, they also affect radio-
sensitizing effects in combined radiochemotherapy, since
necessary drug levels are not reached in tumors.
Ionizing radiation has been shown to enhance cellular
resistance to anticancer drugs, including methotrexate,
6-thioguanine, cisplatin and others [58,59]. Hill et al.
were the first to report that in vitro exposure of mam-
malian cells to fractionated irradiation results in the
expression of a multidrug resistance phenotype with
cross-resistance to Vinca alkaloids, epipodophyllotoxins
and colchicine, but not to anthracyclines [60]. These cell
lines revealed an overexpression of P-glycoprotein, but
not of MDR1 mRNA. Studies to elucidate the reason for
increased protein but unchanged mRNA levels upon X-
irradiation revealed a slower turnover of P-glycoprotein
in X-irradiated cells(half life: 40 h) relative to classical
drug-selected sublines (half life: 17 h), indicating that P-
glycoprotein gp overexpression may be differently regu-
lated in these sublines at the translational level [61].
These data clearly show that the development of drug
resistance following X-irradiation arise by a mechanism
distinct from that operating after drug selection. Fractio-
nated irradiation of a human epidermoid lung carci-
noma xenograft grown in nude mice also results in
overexpression of P-glycoprotein without concomitant
MDR1 mRNA overexpression [62]. This in vivo
approach mimics the clinical situation and points to a
possible role of irradiation for P-glycoprotein overex-
pression and induction of drug resistance in radioche-
motherapy. Subsequently, similar results have been
found for MRP1. Fractionated X-irradiation increased
resistance of tumor cell lines to anticancer drugs and
induced expression of MRP1 [63-65].
Nitroimidazoles have been coupled to sugar mole-
cules, since hypoxic tumors reveal higher glycolysis
and higher membrane transporter-mediated glucose
uptake [66]. Hybrid molecules of sugars and nitroimi-
dazoles (e.g. TX-2224) showed increased cellular
uptake and at the same time radio-sensitizing activity
[67]. Similarly, ifosfamide has been coupled to sugars
(glufosfamide) to sensitize hypoxic tumors for radio-
chemotherapy [68]. Increased glucose uptake in
hypoxic and radio-resistant tumors is also the rationale
for using 2-deoxy-D-glucose (2-DG). This compound
inhibits the first enzyme of glycolysis (hexokinase),
increases metabolic oxidative stress in tumor cells and
sensitizes tumor cells towards radiation [69,70]. Many
natural products have been described to exert radio-
sensitizing effects and affect function and expression of
transport proteins at the same time. For instance, the
radiosensitizing trichostatin A down-regulates P-glyco-
protein (MDR1) expression [71].
On the other hand, over-expression of MDR1 or
MRP1 confers resistance towards geldanamycin and its
derivative, 17-allylamino-demethoxygeldanamycin (17-
AAG) [72,73]. Both compounds reveal radio-sensitizing
effects by inhibition of the heat shock protein, HSP90.
Wortmannin inhibits the P-glycoprotein function [74],
and a wortmannin-dependent PI3K/Akt inhibition cor-
relates with reduced MRP1 expression [75]. Interest-
ingly, wortmannin also inhibits the insulin-induced
activation of the GLUT4 glucose transporter [76]. Glu-
cose transporters are of prognostic value as reported for
ovarian carcinoma [77]. Poorly differentiated tumors
showed a trend to over-express the GLUT1 protein
compared with the more differentiated counterparts.
Patients who experienced a complete clinical response
to chemotherapy were more frequently GLUT1 positive
than GLUT1 negative. In multivariate analysis of
advanced stage disease, residual tumor and high GLUT1
expression levels were the only independent variables
that maintained a significant association with response
to chemotherapy. In Stage III-IV patients showing a
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associated with a shorter disease-free survival.
Resveratrol and many other polyphenolic compounds
inhibit P-glycoprotein and other ABC transporters in
terms of function and expression [78,79]. The fact that
resveratrol and other flavonoids act as inhibitors of P-
glycoprotein raised much interest, because clinical trials
with synthetic compounds to modulate the function of
P-glycoprotein were not very promising yet [80,81].
Most of these resistance-modifying agents are too toxic
at the required doses. Therefore, the search for P-glyco-
protein inhibitors from the field of natural products may
be more promising, since many natural products and
phytotherapeutics are appreciated for their low side
effects and good tolerability. As P-glycoprotein detoxi-
fies xenobiotic compounds in normal tissues taken up
with food, it can be expected that many herbal com-
pounds are substrates of this efflux transporter. Indeed,
there is a large body of evidence that natural com-
pounds are transported by P-glycoprotein. From an evo-
lutionary point of view, substrates and inhibitors of P-
glycoprotein have been frequently co-developed in the
same plant species. Plants developed secondary metabo-
lites during evolution of life to defend against predators
such as herbivores. If herbivores detoxify harmful nat-
ural products by P-glycoprotein, plants need inhibitors
of P-glycoprotein for efficient self-defense. Hence it can
be speculated that many P-glycoprotein inhibitors
should be present in plants [82]. During the past years,
P-glycoprotein-inhibiting activities have frequently been
observed. The large number of data can be separated in
two major categories: natural products either function-
ally inhibit P-glycoprotein byi n t e r f e r e n c ew i t he f f l u x
activity of the drug pump or they down-regulate P-gly-
coprotein/MDR1 expression, thereby re-sensitizing mul-
tidrug-resistant cells [83]. Some of these compounds
inhibit not only P-glycoprotein, but also MRP1 [84-86]
or BCRP [86-88]. It has not yet unequivocally been clar-
ified, whether large amounts of polyphenols taken up
with fruits and vegetables may influence absorption, dis-
tribution, and secretion of drugs in general or
radiosensitizers.
Transport of radioprotectors
The use of radioprotective agents in cancer therapy
raises the question, how normal tissues, but not tumors
can selectively be protected. Specific transport process
may be helpful for the development of such strategies.
Amifostine (WR-2721) and its derivatives are phos-
phoaminothionates. As pro-drugs, they are depho-
sphorylated by alkaline phosphatase. The metabolite,
WR 1065, passively diffuses through the cell membrane
and is oxidized to a disulfide, WR-33278. As this com-
pound reveals chemical similarity to polyamine
spermine, it is then transported by the ornithine decar-
boxylase (ODC)-antizyme (OAZ)-dependent polyamine
transporter leading to cellular accumulation of amifos-
tine derivatives [90,91]. A selective radioprotection of
normal but not tumor cells may be achieved by trans-
fection of OAZ c D N A .T h e r e b y ,t h ep o l y a m i n et r a n s -
porter and, hence, WR-33278 uptake is inhibited. Since
tumor cells reveal higher ODC activities and polyamine
contents as normal tissues, a combination therapy of
amifostine and OAZ gene transfer may result in an
increased eradication of tumor cells with protection of
normal tissues at the same time [92].
The topical application of radioprotectors in the form
of creams and ointments for airline employees, depends
on dermal absorption. The passage through the Stratum
corneum to the epidermis and dermis is not only influ-
enced by the radio-protecting agent itself, but also by
the formulation, as shown for amifostine (WR-2721)
[93].
Remarkably, radiosensitivity also depends on the
expression of drug transporters independently of a
simultaneous application of radio-protective or radio-
sensitizing agents. The retroviral transfer of the MDR1
gene induced differential expression of genes, including
up-regulation of detoxifying and down-regulation of
pro-apoptotic genes [94]. Hence, it can be speculated
that MDR1-based gene therapy as well as induction of
MDR1 gene expression by chemical agents (e.g.s m a l l
molecules) may favor the protection of normal tissues
from radiation-induced damage [95] (Figure 3).
The efficacy of radiochemotherapy is also determined
by transporter-independent processes. In response to
gamma-ray, whole body irradiation, changes in the
intestinal membrane fluidity and lipid peroxidation have
been observed [96]. Membrane fluidity is an important
factor for the cellular uptake and accumulation of drugs.
Vitamin E and its main isomer, a-tocopherol are very
h y d r o p h o b i ca n dc a n n o tb ef r e e l yd i s t r i b u t e di nt h e
blood stream. Rather, they associate with lipoproteins
sharing many features with lipoprotein metabolism and
cholesterol transport [97,98]. In addition to passive dif-
fusion in the colon, active uptake by the transmembrane
glycoprotein, scavenger receptor-class BI (SCARB1,
SRBI), plays a role. The microsomal triglyceride transfer
protein is required for enterocytic secretion of vitamin E
into chylomicrons. Apparently, different transport sys-
tems are necessary for tissue distribution. In addition to
SR-BI, tocopherol-associated proteins (TAP), phospholi-
pid transfer protein (PLTP) and various other transport
and transfer proteins of the lipid and cholesterol meta-
bolism have been described, e.g. the ABCA1 transporter,
the cholesterylester transfer protein (CETP), LDL-and
HDL- receptors and others. SR-BI also plays a role for
the selective a-tocopherol uptake across the blood brain
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occurs via the a-tocopherol transfer protein (a-TTP).
T h ee x c r e t i o nt a k e sp l a c ev i ab i l ea n du r i n e .A B C
transporters in the canalicular membranes of hepato-
cytes contribute to biliary excretion. a-tocopherol is
excreted as carboxyethyl-hydroxychromane.
Conclusions and Perspectives
Taking the research progress in this field into considera-
tion, a number of issues appear that have not adequately
been addressed as yet:
(1) The relationships between drug and radio-resis-
tance are incompletely understood. The elucidation
of underlying molecular mechanisms is necessary to
take advantage of synergistic effects for tumor ther-
apy and of antagonistic effects to protect healthy tis-
sues. Transport process plays an eminent role in this
context. Solid data are available for P-glycoprotein
providing evidence for the relevance of transport pro-
cesses of radiopharmaceuticals and -modulators. The
vast majority of other transport proteins have been
scarcely investigated and their role for radiotherapy
and radiochemotherapy is not understood yet.
(2) Many single results provide strong evidence for
the importance of transport processes for radiophar-
maceuticals and-modulators. However, a systematic
synopsis integrating and validating existing single
results is still missing. This may, however, be rele-
vant for the realization of novel diagnostic and ther-
apeutic strategies.
(3) The translation of results of basic research to the
clinical everyday routine has to be considerably
improved and accelerated from our point of view.
The radiotracer and P-glycoprotein substrate Tm
99-
sestamibi is a suitable example to illustrate the clini-
cal relevance of transport processes of radiopharma-
ceuticals. There is an enormous potential for other
applications in radiology and nuclear medicine based
on drug transport. The inter-connection of theoreti-
cal and experimental expertise in this field repre-
sents a critical mass to foster the progress for novel
diagnostic and therapeutic approaches.
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